Why the study?
Do oral anticoagulants prevent ischemic stroke in patients with nonvalvular atrial fibrillation?
Do oral anticoagulants prevent ischemic stroke in patients with nonvalvular atrial fibrillation?
This review discusses the risks and benefits of oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation, emphasizing risk stratification tools.
Answers are grounded in this paper and cite their sources.
Risk stratification guides anticoagulation decisions in nonvalvular AF; leaves open optimal tool selection amid newer agents.
Atrial fibrillation is the most common, serious, cardiac arrhythmia and increases the risk for ischemic stroke fivefold. Nonvalvular atrial fibrillation may be responsible for up to 15-20% of strokes. Antiplatelet agents and oral anticoagulants are used for stroke prevention in atrial fibrillation. The following review article discusses the potential risks and benefits of oral anticoagulants in nonvalvular atrial fibrillation with particular emphasis on accurate risk stratification tools for ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Nagra et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: